用治疗瘤的维护疗法加上特莫佐洛米德与特莫佐洛米德单独治疗质母细胞瘤:一项随机临床试验
Roger Stupp1, Sophie Taillibert2, Andrew A Kanner3
1University Hospital Zurich and University of Zurich, Zurich, Switzerland2Lausanne University Hospital (CHUV), Lausanne, Switzerland.
JAMA
|December 17, 2015
概括
添加瘤治疗场 (TTFields) 于泰莫索洛米德维持疗法显著改善了质母细胞瘤患者在化疗后的无进展和整体存活率.
科学领域:
- 神经瘤学
- 医学物理
- 临床试验研究
背景情况:
- 质母细胞瘤是一种具有不良预后的侵袭性脑癌.
- 标准治疗包括手术,放射和化疗.
- 新的治疗方法对于改善患者的结果至关重要.
研究的目的:
- 评估结合瘤治疗领域 (TTFields) 与泰莫佐洛米德维持治疗的疗效和安全性.
- 评估TTFields作为质母细胞瘤患者化学辐射后标准护理的辅助剂.
主要方法:
- 在质母细胞瘤患者中,随机对照试验比较了TTFields加temozolomide与temozolomide单独使用.
- 在完成化疗后,患者接受了维持治疗.
- 这项研究涉及695名在315名患者的临时分析中随机选择的患者.
主要成果:
- TTFields加上泰莫索洛米德显著改善了无病变存活率 (7. 1个月与4. 0个月).
- 在TTFields和temozolomide组中,整体存活时间也显著延长 (20.5个月与15.6个月).
- 组合治疗耐受性良好,没有发现新的安全问题.
结论:
- 将TTFields添加到维护用temozolomide中显著提高了质母细胞瘤患者的生存结果.
- 对于质母细胞瘤来说,TTField是一种有前途的治疗方案,可以改善标准治疗方案.
- 这一中间分析支持TTFields在质母细胞瘤治疗中的持续研究和潜在的临床应用.
相关概念视频
01:27Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:56Treatment Resistent Cancers
1.5K
1.5K